Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 27, 2025Frontiers in ImmunologyOpen Access

Clinical, immunological, molecular characteristics and outcomes of stem cell transplantation in ZAP70 deficiency: a single-center experience

View Full Paper
Ask AI
Bookmark
Share

Authors

FAFai AlQahtaniASAzhar Al ShaqaqBABandar Al‐Saud

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals HSCT effectiveness and challenges in ZAP70 deficiency patients, suggesting tailored approaches.

Key Points

  • Complete immune reconstitution achieved in 73% of patients after HSCT, indicating promising outcomes.
  • Initial symptoms included respiratory infections and skin issues, with many patients experiencing autoimmune complications.
  • Transplants utilized varied donor types, with myeloablative conditioning enhancing immune recovery.
  • Patients with severe infections may benefit from reduced-intensity HSCT, though additional treatments could be needed.

Cite This Study

AlQahtani et al. (2025) studied this question.

synapsesocial.com/papers/68d7be66eebfec0fc5237c9ahttps://doi.org/10.3389/fimmu.2025.1656240
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1ZAP-70 mutation: a case with familial autoimmune haemolytic anaemia and immune deficiency2024 · 1 citations
  2. 2The Experience of a Tertiary Reference Center in Central Anatolia with Children Carrying ZAP-70 Variants, Including Two Novel Variants2026
  3. 3Real-World Challenges of Haplo-Identical Hematopoietic Stem Cell Transplant in a Developing Country: A Single Center Experience2024 · 1 citations
  4. 4<scp>HLA</scp>‐haploidentical stem cell transplantation in children with inherited bone marrow failure syndromes: A retrospective analysis on behalf of <scp>EBMT</scp> severe aplastic Anemia and pediatric diseases working parties2024 · 14 citations
  5. 5Shifting paradigms from myeloablation to immune modulation: pre-transplant immune-suppression and post-transplant cyclophosphamide in human leucocyte antigen identical related donor hematopoietic stem cell transplantation for sickle cell disease2026